Core Insights - The medical bed industry in China is experiencing steady growth, with the market size reaching 15.184 billion yuan in 2023 and projected to grow to approximately 17.363 billion yuan in 2024, driven by an aging population and increasing demand for medical services [1][9]. Industry Definition and Classification - Medical beds, also known as healthcare beds, are specialized equipment designed for medical institutions, providing a safe and comfortable platform for patient diagnosis, treatment, care, and rehabilitation [1]. Industry Chain Analysis - The medical bed industry chain consists of four main segments: upstream raw materials and components supply, midstream manufacturing, downstream application services, and supporting industries. The upstream includes suppliers of metals, plastics, and electronic components, while midstream manufacturers produce various types of medical beds. Downstream applications cover hospitals, nursing homes, and home care, with a focus on after-sales services [3]. Development History - The Chinese medical bed industry has evolved over 40 years from reliance on imports to self-innovation. The industry has progressed through several phases: initial reliance on foreign technology, rapid domestic growth driven by healthcare reforms, and the current phase of high-quality development focusing on technology integration and green manufacturing [5]. Current Industry Status - The medical bed market in China is diverse, with ordinary beds holding a significant market share, while multifunctional and electric beds are growing rapidly. The increasing elderly population is expected to drive demand for specialized medical beds [9][12]. Downstream Application Analysis - Hospitals dominate the downstream application of medical beds, accounting for 68% of the market, followed by nursing homes at 18% and home care at 12%. Other institutions, such as rehabilitation centers, make up 2% [12]. Key Enterprises Analysis - The competitive landscape of the medical bed industry is diverse, with companies like Mindray focusing on high-end, intelligent medical beds, while others like Xinhua Medical offer a wide range of products. Companies such as Kofor Medical and Sykon Medical specialize in specific market segments, contributing to a complex competitive environment [14][18]. Future Development Trends - The future of the medical bed industry is expected to focus on high-end technology integration, lightweight materials, and multifunctional designs. High-end beds will incorporate smart sensors and AI for real-time monitoring, while lightweight designs will enhance mobility and comfort. Multifunctional beds will enable various clinical applications, improving efficiency and patient care [20][21][23].

数据来源：天天基金 截止至20250423 截至一季度，景顺长城新兴成长A前十大重仓股为山西汾酒、贵州茅台、五粮液、海大集团、迈瑞医 疗、古井贡酒、泸州老窖、美的集团、中国中免、晨光股份。 专题：2025基金一季报：最新持仓曝光！ 2025年一季度收官，百亿规模以上的权益类基金业绩呈现显著分化，基金经理的调仓能力与行业配置策 略经受考验。 作为曾经的公募基金"千亿顶流"，刘彦春的调仓策略和业绩表现一直备受市场关注。目前，刘彦春管理 的基金资产总规模约为410.20亿元，距其2021年第二季度1163.01亿元的规模高点已经下跌一半以上。 | 序号 | 名称 | 管理规模 ▼ | 管理基金数 | 年初至今 基金公司 | | | --- | --- | --- | --- | --- | --- | | | 张坤偏股型指数 | 608.22亿 | 4 | 3.49% | 易方达基金 | | 2 | 刘彦春偏股型指数 | 410.20亿 | 6 | -0.19% | 景顺长城基金 | | 3 | 葛兰偏股型指数 | 404.47亿 | 3 | 3.24% | 中欧基金 | | 4 | 谢治宇偏股型指数 | 397. ...

金十图示：2025年04月23日（周三）富时中国A50指数成分股今日收盘行情一览：银行、半导体行业午后延续跌势 保险 中国太保 中国人保 中国平安 电机 3175.28亿市值 2972.69亿市值 9232.59亿市值 6.46亿成交额 15.15亿成交额 3.17亿成交额 50.70 7.18 30.90 -0.07(-0.23%) +0.13(+0.26%) +0.03(+0.42%) 酸酒行业 贵州茅台 五粮液 山西汾酒 19496.19亿市值 2620.00亿市值 5044.93亿市值 28.95亿成交额 12.47亿成交额 9.73亿成交额 1552.00 129.97 214.76 -3.19(-1.46%) +3.20(+0.21%) -0.13(-0.10%) 半导体 北方华创 寒武纪-U 海光信息 HYGON 2433.47亿市值 2860.46亿市值 3463.26亿市值 21.92亿成交额 19.14亿成交额 37.76亿成交额 455.79 685.21 149.00 -3.10(-2.04%) -6.06(-1.31%) -9.77(-1.41%) 汽车整车 铁路公路 比亚迪 长城汽 ...

Core Viewpoint - The report from China Europe Fund highlights the performance and strategic outlook of three funds managed by renowned fund manager Ge Lan, focusing on the healthcare and innovation sectors, indicating a positive trend in the Chinese pharmaceutical and medical device markets [1][3]. Fund Performance - The largest fund, China Europe Healthcare Mixed Fund, reported a net value growth rate of 2.37% for Class A shares and 2.17% for Class C shares, outperforming the benchmark return of 0.46% during the same period [3]. - The top ten holdings of the fund include major companies such as Heng Rui Medicine, WuXi AppTec, and Mindray Medical, with notable changes in the portfolio compared to the end of 2024 [3]. Market Environment - The overall policy environment continues to support innovation while reinforcing compliance, with the National Medical Insurance Administration exploring a new category for Class B drugs, which expands payment options for innovative drugs [3]. - The normalization of anti-corruption and price governance in the pharmaceutical sector is leading companies to enhance their academic promotion systems, fostering a healthier and more sustainable domestic medical market [3]. Innovation and Collaboration - The report emphasizes the acceleration of research and development in innovative drugs, particularly in areas like multi-antibody and ADC technologies, with increasing collaboration between domestic companies and international firms [4]. - Key clinical data disclosures and ongoing global partnerships are expected to enhance the competitiveness of Chinese companies in the ADC, multi-antibody, and peptide sectors [4]. Consumer Healthcare and Medical Devices - The consumer healthcare sector is anticipated to see structural opportunities, particularly in aesthetic medicine and ophthalmology, driven by rising health management awareness among residents [4]. - The demand for home medical devices is projected to grow steadily due to the aging population, while the medical device sector is recovering, with significant growth in domestic bidding data observed in the first quarter [4].

从指数持仓来看，中证全指医疗行业指数十大权重分别为：迈瑞医疗（14.15%）、爱尔眼科 （8.89%）、联影医疗（7.82%）、爱美客（4.05%）、惠泰医疗（4.0%）、鱼跃医疗（3.12%）、上海 医药（3.09%）、新产业（3.03%）、益丰药房（2.65%）、美年健康（2.5%）。 金融界4月22日消息，A股三大指数收盘涨跌不一，中证全指医疗行业指数 (医疗行业，932131)报537.08 点。 数据统计显示，中证全指医疗行业指数近一个月下跌5.24%，近三个月下跌0.28%，年至今下跌5.24%。 据了解，中证全指行业优选指数系列从中证全指行业中选取符合一定流动性与市值筛选条件的上市公司 作为指数样本，以反映各个行业内较具代表性与可投资性的上市公司证券的整体表现。该指数以2021年 12月31日为基日，以1000.0点为基点。 资料显示，指数样本每半年调整一次，样本调整实施时间分别为每年6月和12月的第二个星期五的下一 交易日。权重因子随样本定期调整而调整，调整时间与指数样本定期调整实施时间相同。在下一个定期 调整日前，权重因子一般固定不变。遇临时调整时，当中证全指指数调整样本时，中证全指行业指数 ...

创业板指的个股、行业和风格的风险敞口较大，高成长高弹性特征显著。2012年以来，创业板指最大上 涨达570%，最大回撤逾70%，在宽基中具有较高的弹性空间和成长性。 创业板100ETF华夏（159957）管理费率0.15%，托管费率0.05%，为同类产品场内最低水平，助力投资 者低费率布局创业板。 数据显示，截至2025年3月31日，创业板指数(399006)前十大权重股分别为宁德时代(300750)、东方财富 (300059)、汇川技术(300124)、迈瑞医疗(300760)、阳光电源(300274)、温氏股份(300498)、中际旭创 (300308)、新易盛(300502)、亿纬锂能（维权）(300014)、爱尔眼科(300015)，前十大权重股合计占比 50.27%。 MACD金叉信号形成，这些股涨势不错！ ETF方面，截至收盘，创业板100ETF华夏(159957)下跌0.16%，最新报价1.26元，收盘成交额已达 2322.62万元，换手率1.33%。 资金流入方面，创业板100ETF华夏近10个交易日内，合计"吸金"2864.16万元。 值得注意的是，该基金跟踪的创业板指数估值处于历史低位，最 ...

金十图示：2025年04月22日（周二）富时中国A50指数成分股今日收盘行情一览：银行股全天走势分化，保险行业午后转涨 长江电力 中国核电 东方财富 8 1939.56亿市值 3243.93亿市值 7176.53亿市值 22.70亿成交额 8.57亿成交额 34.61亿成交额 29.33 9.43 20.55 +0.02(+0.07%) +0.05(+0.53%) -0.08(-0.39%) 证券 食品饮料 中信证券 国泰海通 海天味业 胸更 3716.99亿市值 3007.63亿市值 2346.02亿市值 11.58亿成交额 6.80亿成交额 2.80亿成交额 17.06 42.19 25.08 -0.15(-0.59%) +0.07(+0.41%) +0.03(+0.07%) 消费电子 化学制药 恒瑞医药 工业富联 立讯精密 3251.38亿市值 3530.91亿市值 2195.96亿市值 31.40亿成交额 8.19亿成交额 31.17亿成交额 17.78 30.30 50.97 -0.03(-0.17%) -0.57(-1.85%) +1.80(+3.66%) 家电行业 农牧饲渔 牧原股份 格力电器 ...

Group 1 - The ChiNext 50 Index (399673) has decreased by 0.43% as of April 22, 2025, with mixed performance among constituent stocks [1] - Nanda Optoelectronics (300346) led the gains with an increase of 4.40%, while Zhifei Biological (300122) experienced the largest decline at 7.09% [1] - The ChiNext 50 ETF (159367) has seen a slight decrease of 0.45%, with the latest price at 0.89 yuan [1] Group 2 - The ChiNext 50 ETF closely tracks the ChiNext 50 Index, which consists of the 50 stocks with the highest average daily trading volume in the ChiNext market [2] - As of March 31, 2025, the top ten weighted stocks in the ChiNext 50 Index account for 64.18% of the index, with CATL (300750) having the highest weight at 24.47% [2][4] - The top ten stocks include notable companies such as Mindray Medical (300760) and Yongsun Electric (300274) [4] Group 3 - The ChiNext 50 ETF has a management fee rate of 0.15% and a custody fee rate of 0.05%, which are the lowest among comparable funds [1] - The index's valuation is at a historical low, with a price-to-book ratio (PB) of 4.35, lower than 85.48% of the time over the past five years, indicating strong valuation attractiveness [1] - The ETF has shown a cumulative increase of 1.25% over the past week, ranking 1 out of 9 among comparable funds [1]

Core Viewpoint - The China Securities Index for Healthcare Equipment and Services has shown a recent increase, but it has experienced declines over the past month, three months, and year-to-date [1]. Group 1: Index Performance - The CSI Healthcare Equipment and Services Index rose by 1.17% to 13,221.28 points with a trading volume of 10.971 billion [1]. - Over the past month, the index has decreased by 9.68%, by 0.46% over the last three months, and by 4.54% year-to-date [1]. Group 2: Index Composition - The index is composed of listed companies in the healthcare sector, reflecting the overall performance of these securities [1]. - The top ten weighted companies in the index include Mindray Medical (9.26%), Aier Eye Hospital (8.31%), and United Imaging Healthcare (7.36%) [1]. - The index's holdings are primarily from the Shenzhen Stock Exchange (60.12%) and the Shanghai Stock Exchange (39.88%) [1]. Group 3: Fund Tracking - Public funds tracking the healthcare index include several funds such as Southern CSI Healthcare Equipment and Services Link A, Tianhong CSI Healthcare Equipment and Services ETF, and others [2].

金融界2025年4月21日消息，中欧医疗健康混合A(003095) 最新净值1.5603元，增长1.85%。该基金近1个 月收益率-1.41%，同类排名1379|4672；近3个月收益率2.56%，同类排名1469|4599；今年来收益 率-0.54%，同类排名2715|4590。 公开资料显示，中欧医疗健康混合A基金成立于2016年9月29日，截至2024年12月31日，中欧医疗健康 混合A规模159.10亿元，基金经理为葛兰。 简历显示：葛兰女士:中国籍。美国西北大学生物医学工程专业博士。历任国金证券股份有限公司研究 所研究员,民生加银基金管理有限公司研究员。2014年10月加入中欧基金管理有限公司,曾任研究员、中 欧明睿新起点灵活配置混合型证券投资基金基金经理(2015年1月29日起至2016年4月22日)、中欧瑾泉灵 活配置混合型证券投资基金基金经理(2015年3月16日起至2016年4月22日)、中欧瑾源灵活配置混合型证 券投资基金基金经理(2015年3月31日起至2016年4月22日)、中欧瑾和灵活配置混合型证券投资基金基金 经理(2015年4月13日起至2016年4月22日)。现任中欧医疗健康混 ...